Gilead's Truvada Sales on Light Side

Updated from 4:34 p.m. EST

While Gilead Sciences (GILD Quote) saw its fourth-quarter revenue jump, the company reported mixed sales results for some of its major drugs, sending its shares lower in after-hours trading.

According to Gilead, fourth-quarter revenue rose 65% from a year ago, and product sales climbed for the ninth straight quarter thanks to its HIV drug Truvada and hepatitis B treatment Hepsera.

Sales of Truvada, the company's biggest HIV drug, rose 18% from the third quarter to $191.1 million, but analysts were disappointed. Forecasters expected Truvada sales to reach $197 million. The drug, which launched in the U.S. in the third quarter of 2004 and in certain European countries in 2005, accounted for 50% of Gilead's total HIV product sales for the fourth quarter. ...